Infliximab  	Infliximab  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
ulcerative  	ulcerative  	 NNS	B-NP
colitis  	colitis  	 VBP	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
infliximab  	infliximab  	 NN	I-NP
for  	for  	 IN	O
moderately  	moderately  	 RB	O
to  	to  	 TO	O
severely  	severely  	 RB	O
active  	active  	 JJ	O
ulcerative  	ulcerative  	 JJ	B-NP
colitis  	colitis  	 NNS	I-NP
( 	( 	 -LRB-	O
UC 	UC 	 NNP	B-NP
)  	)  	 -RRB-	O
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellent  	Excellent  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission  	submission  	 NN	O
indicated  	indicated  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
infliximab  	infliximab  	 NNS	B-NP
( 	( 	 -LRB-	O
5  	5  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
kg 	kg 	 CD	I-NP
)  	)  	 -RRB-	O
had  	had  	 VBD	O
been  	been  	 VBN	O
demonstrated  	demonstrated  	 VBN	O
in  	in  	 IN	O
terms  	terms  	 NNS	O
of  	of  	 IN	O
higher  	higher  	 JJR	O
response  	response  	 NN	B-NP
rates  	rates  	 NNS	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
sustained  	sustained  	 JJ	O
response  	response  	 NN	O
in  	in  	 IN	O
health-related  	health-related  	 JJ	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
For  	For  	 IN	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
analysis 	analysis 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
manufacturer  	manufacturer  	 NN	B-NP
built  	built  	 VBD	O
a  	a  	 DT	O
Markov  	Markov  	 JJ	B-NP
model  	model  	 NN	I-NP
to  	to  	 TO	O
compare  	compare  	 VB	O
infliximab  	infliximab  	 VBN	O
with  	with  	 IN	O
standard  	standard  	 JJ	O
care 	care 	 NN	O
.  	.  	 .	O
It  	It  	 PRP	O
estimated  	estimated  	 VBD	O
the  	the  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
quality-adjusted  	quality-adjusted  	 JJ	B-NP
life-year  	life-year  	 NN	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
gained  	gained  	 VBD	O
was  	was  	 VBD	O
between  	between  	 IN	O
25,044  	25,044  	 CD	O
pounds  	pounds  	 NNS	O
and  	and  	 CC	O
33,866  	33,866  	 CD	O
pounds  	pounds  	 NNS	O
depending  	depending  	 VBG	O
on  	on  	 IN	O
the  	the  	 DT	O
strategy  	strategy  	 NN	O
used 	used 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
report  	report  	 NN	O
generally  	generally  	 RB	O
agreed  	agreed  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	O
on  	on  	 IN	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
infliximab  	infliximab  	 NN	B-NP
for  	for  	 IN	I-NP
subacute  	subacute  	 JJ	I-NP
exacerbations  	exacerbations  	 NN	I-NP
of  	of  	 IN	I-NP
UC 	UC 	 NNP	I-NP
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
several  	several  	 JJ	O
areas  	areas  	 NNS	O
of  	of  	 IN	O
uncertainty 	uncertainty 	 NN	O
,  	,  	 ,	O
of  	of  	 IN	O
which  	which  	 WDT	O
the  	the  	 DT	O
interpretation  	interpretation  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
importance  	importance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
quality  	quality  	 NN	O
of  	of  	 IN	O
life  	life  	 NN	B-NP
changes  	changes  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
subacute  	subacute  	 JJ	B-NP
situation  	situation  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
adequacy  	adequacy  	 NN	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	O
of  	of  	 IN	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
infliximab  	infliximab  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
acute  	acute  	 JJ	O
hospital-based  	hospital-based  	 JJ	O
situation  	situation  	 NN	O
were  	were  	 VBD	O
considered  	considered  	 VBN	O
pre-eminent  	pre-eminent  	 JJ	O
by  	by  	 IN	O
the  	the  	 DT	O
ERG 	ERG 	 NNP	O
.  	.  	 .	O
This  	This  	 DT	O
challenged  	challenged  	 VBN	O
the  	the  	 DT	O
estimates  	estimates  	 NNS	O
of  	of  	 IN	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
offered  	offered  	 VBN	O
and  	and  	 CC	O
suggested  	suggested  	 VBD	O
that  	that  	 IN	O
there  	there  	 EX	O
should  	should  	 MD	O
be  	be  	 VB	O
a  	a  	 DT	O
separate  	separate  	 JJ	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
infliximab  	infliximab  	 NN	B-NP
for  	for  	 IN	O
acute  	acute  	 JJ	O
exacerbations  	exacerbations  	 NN	B-NP
of  	of  	 IN	O
moderately  	moderately  	 RB	O
to  	to  	 TO	O
severely  	severely  	 RB	O
active  	active  	 JJ	O
UC 	UC 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
NICE  	NICE  	 NNP	O
guidance  	guidance  	 VBD	O
issued  	issued  	 VBN	O
in  	in  	 IN	O
April  	April  	 NNP	O
2008  	2008  	 CD	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that 	that 	 IN	O
:  	:  	 :	O
infliximab  	infliximab  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
recommended  	recommended  	 VBN	O
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
subacute  	subacute  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
of  	of  	 IN	O
moderately  	moderately  	 RB	O
to  	to  	 TO	O
severely  	severely  	 RB	O
active  	active  	 JJ	O
UC 	UC 	 NNP	B-NP
.  	.  	 .	O
